"Which COVID-19 Vaccine Stock Should Investors Consider?"

Pfizer, Moderna, and AstraZeneca's stocks have seen a significant decline from their pandemic highs, leading investors to wonder if now is a good time to buy. Pfizer has a pipeline of drugs and vaccines beyond its COVID-19 vaccine, with expected earnings growth despite a drop in COVID-19 vaccine sales. Moderna's focus is on mRNA-based therapies, but its earnings are forecasted to decline due to a reliance on COVID-19 vaccine sales. AstraZeneca has stable growth and a diverse therapeutic portfolio, with anticipated earnings and sales growth. Pfizer's valuation appears the most compelling, trading at a discount to industry averages, while Moderna's sales expansion offers optimism. Overall, these healthcare companies are trading at more reasonable valuations, considering their earnings potential.